265 related articles for article (PubMed ID: 27158367)
1. Systemic delivery to central nervous system by engineered PLGA nanoparticles.
Cai Q; Wang L; Deng G; Liu J; Chen Q; Chen Z
Am J Transl Res; 2016; 8(2):749-64. PubMed ID: 27158367
[TBL] [Abstract][Full Text] [Related]
2. An Elvitegravir Nanoformulation Crosses the Blood-Brain Barrier and Suppresses HIV-1 Replication in Microglia.
Gong Y; Zhi K; Nagesh PKB; Sinha N; Chowdhury P; Chen H; Gorantla S; Yallapu MM; Kumar S
Viruses; 2020 May; 12(5):. PubMed ID: 32443728
[TBL] [Abstract][Full Text] [Related]
3. Functionalized PLGA nanoparticles prepared by nano-emulsion templating interact selectively with proteins involved in the transport through the blood-brain barrier.
Monge M; Fornaguera C; Quero C; Dols-Perez A; Calderó G; Grijalvo S; García-Celma MJ; Rodríguez-Abreu C; Solans C
Eur J Pharm Biopharm; 2020 Nov; 156():155-164. PubMed ID: 32927077
[TBL] [Abstract][Full Text] [Related]
4. Potential use of polymeric nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Bortot B; Ruozi B; Dolcetta D; Vandelli MA; Forni F; Severini GM
Curr Med Chem; 2013; 20(17):2212-25. PubMed ID: 23458620
[TBL] [Abstract][Full Text] [Related]
5. PLGA-PEG-ANG-2 Nanoparticles for Blood-Brain Barrier Crossing: Proof-of-Concept Study.
Hoyos-Ceballos GP; Ruozi B; Ottonelli I; Da Ros F; Vandelli MA; Forni F; Daini E; Vilella A; Zoli M; Tosi G; Duskey JT; López-Osorio BL
Pharmaceutics; 2020 Jan; 12(1):. PubMed ID: 31963430
[TBL] [Abstract][Full Text] [Related]
6. L-Carnitine-conjugated nanoparticles to promote permeation across blood-brain barrier and to target glioma cells for drug delivery via the novel organic cation/carnitine transporter OCTN2.
Kou L; Hou Y; Yao Q; Guo W; Wang G; Wang M; Fu Q; He Z; Ganapathy V; Sun J
Artif Cells Nanomed Biotechnol; 2018 Dec; 46(8):1605-1616. PubMed ID: 28974108
[TBL] [Abstract][Full Text] [Related]
7. Targeting delivery of etoposide to inhibit the growth of human glioblastoma multiforme using lactoferrin- and folic acid-grafted poly(lactide-co-glycolide) nanoparticles.
Kuo YC; Chen YC
Int J Pharm; 2015 Feb; 479(1):138-49. PubMed ID: 25560309
[TBL] [Abstract][Full Text] [Related]
8. Investigation on mechanisms of glycopeptide nanoparticles for drug delivery across the blood-brain barrier.
Tosi G; Fano RA; Bondioli L; Badiali L; Benassi R; Rivasi F; Ruozi B; Forni F; Vandelli MA
Nanomedicine (Lond); 2011 Apr; 6(3):423-36. PubMed ID: 21542682
[TBL] [Abstract][Full Text] [Related]
9. Comparative evaluation of the degree of pegylation of poly(lactic-co-glycolic acid) nanoparticles in enhancing central nervous system delivery of loperamide.
Kirby BP; Pabari R; Chen CN; Al Baharna M; Walsh J; Ramtoola Z
J Pharm Pharmacol; 2013 Oct; 65(10):1473-81. PubMed ID: 24028614
[TBL] [Abstract][Full Text] [Related]
10. Polysorbate 80-coated PLGA nanoparticles improve the permeability of acetylpuerarin and enhance its brain-protective effects in rats.
Sun D; Xue A; Zhang B; Lou H; Shi H; Zhang X
J Pharm Pharmacol; 2015 Dec; 67(12):1650-62. PubMed ID: 26407669
[TBL] [Abstract][Full Text] [Related]
11. PLGA Nanoparticle-Based Formulations to Cross the Blood-Brain Barrier for Drug Delivery: From R&D to cGMP.
Zhi K; Raji B; Nookala AR; Khan MM; Nguyen XH; Sakshi S; Pourmotabbed T; Yallapu MM; Kochat H; Tadrous E; Pernell S; Kumar S
Pharmaceutics; 2021 Apr; 13(4):. PubMed ID: 33917577
[TBL] [Abstract][Full Text] [Related]
12. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
13. Intranasal and intravenous administration of octa-arginine modified poly(lactic-co-glycolic acid) nanoparticles facilitates central nervous system delivery of loperamide.
O'Donnell A; Moollan A; Baneham S; Ozgul M; Pabari RM; Cox D; Kirby BP; Ramtoola Z
J Pharm Pharmacol; 2015 Apr; 67(4):525-36. PubMed ID: 25515568
[TBL] [Abstract][Full Text] [Related]
14. Crossing the blood-brain barrier with nanoparticles.
Zhou Y; Peng Z; Seven ES; Leblanc RM
J Control Release; 2018 Jan; 270():290-303. PubMed ID: 29269142
[TBL] [Abstract][Full Text] [Related]
15. Engineering PLGA nano-based systems through understanding the influence of nanoparticle properties and cell-penetrating peptides for cochlear drug delivery.
Cai H; Liang Z; Huang W; Wen L; Chen G
Int J Pharm; 2017 Oct; 532(1):55-65. PubMed ID: 28870763
[TBL] [Abstract][Full Text] [Related]
16. Exploiting Bacterial Pathways for BBB Crossing with PLGA Nanoparticles Modified with a Mutated Form of Diphtheria Toxin (CRM197): In Vivo Experiments.
Tosi G; Vilella A; Veratti P; Belletti D; Pederzoli F; Ruozi B; Vandelli MA; Zoli M; Forni F
Mol Pharm; 2015 Oct; 12(10):3672-84. PubMed ID: 26312414
[TBL] [Abstract][Full Text] [Related]
17. New approach to treating spinal cord injury using PEG-TAT-modified, cyclosporine-A-loaded PLGA/polymeric liposomes.
Gao SJ; Liu Y; Wang HJ; Ban DX; Cheng SZ; Ning GZ; Wang LL; Chang J; Feng SQ
J Drug Target; 2017 Jan; 25(1):75-82. PubMed ID: 27250819
[TBL] [Abstract][Full Text] [Related]
18. Evolution of blood-brain barrier in brain diseases and related systemic nanoscale brain-targeting drug delivery strategies.
Han L; Jiang C
Acta Pharm Sin B; 2021 Aug; 11(8):2306-2325. PubMed ID: 34522589
[TBL] [Abstract][Full Text] [Related]
19. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
20. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro.
Wang Y; Guo M; Lu Y; Ding LY; Ron WT; Liu YQ; Song FF; Yu SQ
Nanotechnology; 2012 Dec; 23(49):495103. PubMed ID: 23149859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
